DGX

NYSE Healthcare

Quest Diagnostics Incorporated Common Stock

Diagnostics & Research

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

๐Ÿ“Š Market Data
๐ŸŽฏ Investment Strategy Scores

DGX scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 42/100โ–ฒ +5
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 57/100โ–ฒ +3
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 33/100โ–ผ -4
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ‹ Institutional Whale (83/100) โ€” this strategy Large-cap, institutional-quality stocks.

Lowest fit among scored strategies: ๐ŸŽˆ Over-Hyped (33/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find DGX in your text

Paste any article, transcript, or post โ€” the tool will extract DGX and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.